SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will speak at the BIO 2013 International Convention in Chicago, IL on Tuesday, April 23 as part of a panel entitled, "New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection."
Mr. Pritchard will be discussing the company's targeted antibacterial agent against Pseudomonas aeruginosa (Pa), KB001-A. KaloBios is developing KB001-A for the management of Pa in the lungs of patients with cystic fibrosis, while the company's corporate partner Sanofi Pasteur is developing KB001-A for the prevention of ventilator-associated pneumonia caused by Pa.
Breakout Session: Innovations and Opportunities in Vaccines Session ID 1877: New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection When: Tuesday, April 23, 2013, 9:00 – 10:15 AM Where: McCormick Place, Room S402A
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.
Contact: Jeffrey H. Cooper Chief Financial Officer KaloBios Pharmaceuticals, Inc. (650) 243-3146 firstname.lastname@example.org
Media Contact: Joan E. Kureczka Kureczka/Martin Associates Tel: (415) 821-2413 Mobile: (415) 690-0210 Joan@Kureczka-Martin.com
SOURCE KaloBios Pharmaceuticals